Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced that it has initiated the second of its two pivotal trials of Vilazodone, the Company’s novel drug candidate for the treatment of depression. This double-blind, placebo-controlled clinical trial is designed to assess the efficacy and safety of Vilazodone.
Popularity: unranked [?]
